31 Life Sciences Enhanced Tools for COVID-9 Omicron Variant Research
AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognise the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralises its interaction with ACE2. The human ACE2 receptor is found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Research has shown that ACE2 mediates COVID-19 infection through direct binding of the SARS-CoV-2 Spike protein.
AMSBIO’s new Spike neutralising monoclonal antibodies (clone G10xA5 and G10xA1) recognise the SARS-CoV-2 Spike RBD (B.1.1.529, Omicron Variant) protein and neutralise its interaction with ACE2. Both these neutralising antibodies have been functionally tested using the Spike S1 RBD (B.1.1.529, Omicron Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit.
Also new is AMSBIO’s Spike S1 RBD: ACE2 Inhibitor Screening Assay Kit. This key colorimetric assay kit is designed for screening and profiling inhibitors or neutralising antibodies of the interaction between the Omicron variant SARS-CoV-2 Spike RBD and human ACE2. The new assay requires only a few steps to use. Firstly, SARS-CoV-2 Spike RBD (B.1.1.529, Omicron variant) is coated on a 96-well plate overnight. After washing and blocking, the protein is pre-incubated with an inhibitor or neutralising antibody. Following incubation with Biotin-ACE2, the plate is treated with Streptavidin-HRP then addition of a colorimetric HRP substrate to produce colour, which can be quenched and measured using a UV/Vis microplate reader.
Since the beginning of the global pandemic, several new SARS-CoV-2 variants have emerged, each with differing mutations that impact transmissibility, COVID-19 disease severity, and the effectiveness of vaccines. AMSBIO now offers a series of recombinant antigens and pseudotyped lentivirus with key Spike mutations in order to evaluate the efficacy of antibodies and vaccines. These products form part of a larger COVID-19 Tools for Research portfolio, including other high quality recombinant proteins, Spike pseudotyped lentivirus, and reagents for vaccine development and evaluation.
More information online:
ilmt.co/PL/y3vB 56980pr@reply-direct.com
Game-changing Platform Automates Genomics Liquid Handling
The firefly from SPT Labtech is an innovative liquid handling platform for next-generation sequencing (NGS) library preparation.
firefly transforms NGS liquid handling workflows by bringing together pipetting and dispensing within a compact all- in-one design. Along with its hardware capabilities, the platform sets a new standard in powerful, intuitive liquid handling software with multiple user levels, intelligent programming and a fully transparent audit trail. A complementary peer-to-peer cloud-based network- the first of its kind- will allow researchers to share their custom protocols, as well as benefit from SPT Labtech’s validated tools to underpin scientific collaboration and innovation. The launch of firefly builds on SPT Labtech’s strong track record in engineering solutions for genomics applications.
Paul Lomax, Genomics Product Manager at SPT Labtech said: “While advances in next-generation sequencing have revolutionised the genomics field, library preparation methods remain a significant bottleneck for many laboratories. Liquid handling automation offers substantial throughput advantages, overcoming the need for multiple instruments, significant lab space, and high levels of investment. With its all-in-one capabilities, compact design and innovative software, firefly offers a step-change in productivity for genomics laboratories- at an affordable entry point.”
firefly comes application-ready for library preparation kits NEBNext Ultra II DNA; NEBNext Ultra II FS DNA; NEBNext Ultra II RNA, and Illumina DNA Prep with an extended range already under active development.
David Newble, CEO, at SPT Labtech, added: “Our team applies ingenuity to overcome customers’ workflow challenges and accelerate research. We are excited about the potential of the accessible, cost-effective firefly instrument to further democratise the adoption of liquid handling automation for NGS applications. Collaboration is a cornerstone of innovation, and by enabling peer- to-peer knowledge sharing, we aim to empower bigger genomics breakthroughs and advance health.”
More information online:
ilmt.co/PL/ZZma 57232pr@reply-direct.com
New Leptospira Monoclonal Antibodies
Leptospira are spiral shaped bacteria several of which are pathogenic causing the infection Leptospirosis. Animals including dogs and rodents can transmit infection to humans, usually through contact with infected urine. The Leptospira enter the blood stream and can lead to kidney failure or pulmonary bleeding. Recommended treatment is doxycycline.
Pathogenic Leptospira include species such as L. interrogans and L. kirschneri can be differentiated from non-pathogenic species by several markers. Chief among these markers are several outer membrane lipoproteins.
ViroStat is a primary manufacturer, supplying infectious disease reagents to researchers and rapid test manufacturers since 1985. The company has just released a set of new Monoclonal Antibodies to the lipoprotein, LipL41. This is an abundant surface lipoprotein found on pathogenic species of Leptospira. These new antibodies form pairs to detect this marker via ELISA. Thus they have the potential to serve in additional immunoassay detection applications.
Go to the ViroStat website to download the data sheet for these new Monoclonal Antibodies. More information online:
ilmt.co/PL/2D5V
56836pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
